In a BSE filing, Sun Pharmaceutical Industries said: One of the company's wholly-owned subsidiaries has voluntarily requested the USFDA to withdraw approval for 28 Abbreviated New Drug Applications (ANDAs). It further said: These old Money Today, 3 weeks ago
Ranbaxy seeks USFDA nod for withdrawing 28 drug applications - Smart Investor, 3 weeks ago
Sun Pharma arm seeks USFDA nod for voluntary withdrawal of 28 ANDAs of Ranbaxy - First Post.com, 3 weeks ago
Ranbaxy contributes a little lower than Rs 3k cr to the India sales of the merged entityBusiness Standard, 3 weeks ago
NEW DELHI: The Delhi High Court will hear the main arguments in Daiichi Sankyo's case against former Ranbaxy promoters Malvinder and Shivinder Singh in March 2017. This includes the Singh brothers arguments challenging the Japanese drug maker's ...Economic Times, 1 month ago Former Ranbaxy promoter Shivinder Singh to submit asset declarations to Delhi HC within three days Business Standard, 1 month ago
Drugmaker Sun Pharmaceutical Industries has voluntarily requested the United States Food and Drug Administration to withdraw approvals given to 28 Abbreviated New Drug Applications (ANDAs). These older drug products belong to erstwhile Ranbaxy Laboratories ...Business Line, 3 weeks ago
, the U.S. Court of Appeals for the First Circuit upheld a 2014 jury verdict for AstraZeneca (AZ) and Ranbaxy regarding a 2012 payment of $700 million from AstraZeneca for Ranbaxy to abandon its challenge to patents covering Nexium®. Importantly, ...JD Supra, 1 month ago Landmark Court Decision Upheld for Pharmaceutical Industry Uranium Investing News, 1 month ago AstraZeneca, Ranbaxy prevail in landmark pay-for-delay case FiercePharma, 1 month ago ASTRAZENECA : U.S. court upholds AstraZeneca, Ranbaxy win in Nexium antitrust trial 4 Traders, 1 month ago
The 1st US Circuit Court of Appeals has recently ruled in favor of AstraZeneca Plc (NYSE:AZN) and Ranbaxy Laboratories Limited (NYSE:RBXLY) on a long-lasting class action lawsuit involving an illegal agreement between the two companies related to ...4 Traders, 1 month ago AstraZeneca PLC (ADR) (AZN), Ranbaxy Laboratories Limited (ADR) (RBXLY) Wins Over Illegal Deal Case InsiderMonkey.com, 1 month ago
Finasteride Market: Industry Analysis Report, Regional Outlook, Application Development Potential & Forecast, 2016 2024.
"Finasteride market share comprises of Merck Sharp & Dohme, Sun Pharmaceuticals, Ranbaxy Laboratories, Dr. Reddys Laboratories and Intas Pharmaceuticals, Teva Pharmaceuticals, Actavis, Hetero Labs, Yabao Pharmaceuticals, Cipla, Yangtze River Pharma, ...Digital Journal, 1 month ago
Welcome to this week's FiercePharmaAsia report. Takeda announced two dealsat the J.P. Morgan Healthcare Conference—a $5.2 billion proposal to acquire Ariad and another one of $125 million to collaborate with Maverick on T-cell R&D. Valeant , in an ...FiercePharma, 2 days ago
View: 430 The New Year began with the JP Morgan Healthcare Conference— the drug industry's annual investor meet — where industry leaders were busy announcing deals, until Donald Trump accused the industry of getting away with murder. His ...PharmaCompass, 3 days ago
Japanese drug maker Daiichi Sankyo has shut down its India research division as part of the company's overall strategy to increase R&D productivity as the company narrows down its focus to cancer research. The Daiichi Sankyo India Pharma Limited ...Pharmaceutical Tech.com, 3 days ago Daiichi shuts India R&D division Economic Times, 4 days ago Daiichi Sankyo to Shutter Indian R&D Center, 170 Employees Affected Pharma Live, 4 days ago Daiichi Sankyo says Sayonara to India; terminates contract of 170 employees Smart Investor, 4 days ago
More from: , Economic Times...and 1 other sources
on your WebpageAdd Widget >Get your members hooked!